Wire · opportunities
FDA Approves BESREMi for Adults with Essential Thrombocythemia
◆ Sectors
Drug Discovery
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 31 August 2026 · Fusion42 review
The US FDA has approved BESREMi (ropeginterferon alfa-2b-njft) as a new treatment for adults with essential thrombocythemia, the first new option in nearly 30 years.
This Wire brief sits within Fusion42's coverage of Drug Discovery, and 2 sources have reported it.
◆ ◆ The Wire takeaway
Your drug development plans in blood disorders face a new competitor. Moves to develop interferon-based therapies just gained a market foothold with FDA nod for ET treatment.
◆ Coverage
2 sources · 31 Aug 2026
◆ Related on Wire
◆ Topics
Drug Discoveryfda-approvalessential-thrombocythemiadrug-launchoncologyhematology